Government transitioning to less expensive Biosimilars
The provincial government is switching to less expensive Biosimilars.
Beneficiaries currently using one of the originator biologics of Copaxone, Enbrel, Humalog, Humira, Lantus, Lovenox, NovoRapid, Remicade and Rituxan will be transitioned to a less costly biosimilar version on or before March 31, 2024.
Those who are beneficiaries will receive a letter which contains additional information, as well as outlining the next steps needed to transition to a biosimilar.
The Newfoundland and Labrador Prescription Drug Program say the new options are safe and effective.